Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01440101 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Natalizumab (BG00002)
DRUG: Placebo

Sponsor

Biogen